M Tolofoudie1, A Somboro1, B Diarra1, Y S Sarro1, H B Drame1, A C G Togo1, M Sanogo1, A Dembele2, T Togun3, E Nkereuwem3, B Baya1, B Konate4, U Egere3, M Traore5, M Maiga6, K Saliba-Shaw7, B Kampmann3, S Diallo1, S Doumbia1, M Sylla2. 1. University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali. 2. Department of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali. 3. Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia. 4. National Tuberculosis Control Program, Ministry of Health and Public Hygiene, Bamako, Mali. 5. Health Referral Center Five, Ministry of Health and Social Development, Bamako, Mali. 6. Center for Innovation in Global Health Technology, Northwestern University, Chicago, IL, USA. 7. Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND AND OBJECTIVE: Isoniazid preventive therapy (IPT) is known to reduce the risk of developing active TB in about 59% in children aged ⩽15 years. We assessed adherence, completion and adverse events among children who were household contacts of a newly diagnosed adult with smear-positive TB in Bamako, Mali. METHODS: Children aged <15 years living in the same house with an adult smear-positive index case were enrolled in the study in the Bamako Region after consent was obtained from the parent or legal guardian. Adherence was assessed based on the number of tablets consumed during 6 months. RESULTS: A total of 260 children aged <15 years were identified as household contacts of 207 adult patients with smear-positive TB during the study period. Among all child contacts, 130/260 (50.0%) were aged 0-4 years and were eligible for IPT; 128/130 (98.5%) were started on IPT and 83/128 (64.8%) completed with good adherence at the end of the 6 months, and without any significant adverse events. CONCLUSION: We successfully implemented IPT with good acceptance, but low completion rate. The Mali National TB Program and partners should expand this strategy to reach more children in Bamako and the whole country and create greater awareness in the population.
BACKGROUND AND OBJECTIVE: Isoniazid preventive therapy (IPT) is known to reduce the risk of developing active TB in about 59% in children aged ⩽15 years. We assessed adherence, completion and adverse events among children who were household contacts of a newly diagnosed adult with smear-positive TB in Bamako, Mali. METHODS: Children aged <15 years living in the same house with an adult smear-positive index case were enrolled in the study in the Bamako Region after consent was obtained from the parent or legal guardian. Adherence was assessed based on the number of tablets consumed during 6 months. RESULTS: A total of 260 children aged <15 years were identified as household contacts of 207 adult patients with smear-positive TB during the study period. Among all child contacts, 130/260 (50.0%) were aged 0-4 years and were eligible for IPT; 128/130 (98.5%) were started on IPT and 83/128 (64.8%) completed with good adherence at the end of the 6 months, and without any significant adverse events. CONCLUSION: We successfully implemented IPT with good acceptance, but low completion rate. The Mali National TB Program and partners should expand this strategy to reach more children in Bamako and the whole country and create greater awareness in the population.
Authors: M Adjobimey; E Masserey; C Adjonou; G Gbénagnon; V Schwoebel; S Anagonou; J-P Zellweger Journal: Int J Tuberc Lung Dis Date: 2016-08 Impact factor: 2.373
Authors: V F Gomes; C Wejse; I Oliveira; A Andersen; F J Vieira; L J Carlos; C S Vieira; P Aaby; P Gustafson Journal: Int J Tuberc Lung Dis Date: 2011-12 Impact factor: 2.373
Authors: U Egere; A Sillah; T Togun; S Kandeh; F Cole; A Jallow; A Able-Thomas; M Hoelscher; N Heinrich; P C Hill; B Kampmann Journal: Public Health Action Date: 2016-12-21
Authors: Stanzi M le Roux; Mark F Cotton; Jonathan E Golub; David M le Roux; Lesley Workman; Heather J Zar Journal: BMC Med Date: 2009-11-03 Impact factor: 8.775
Authors: James Ayieko; Lisa Abuogi; Brett Simchowitz; Elizabeth A Bukusi; Allan H Smith; Arthur Reingold Journal: BMC Infect Dis Date: 2014-02-20 Impact factor: 3.090